JS207 + JS107

JS207 + JS107 is an investigational combination therapy being developed by Shanghai Junshi Biosciences for the treatment of advanced solid tumors, particularly Claudin18.2-expressing gastrointestinal cancers. The combination consists of two active biologic components: JS207, a recombinant humanized bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A); and JS107, an antibody-drug conjugate (ADC) comprising a humanized anti-Claudin18.2 monoclonal antibody conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE). By combining PD-1/VEGF dual blockade with Claudin18.2-targeted cytotoxic delivery, the regimen aims to synergistically enhance anti-tumor immune responses, inhibit angiogenesis, and induce immunogenic cell death within the tumor microenvironment.